Clinical trialNCT07184619RecruitingPhase 3Interventional

Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia

SponsorNewron Pharmaceuticals SPAEnrollment400Treatment-resistant Schizophrenia

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a prospective, 12-week, randomized, double-blind, placebo-controlled study, designed to evaluate the efficacy, safety, and tolerability of a dose of evenamide of 15 mg bid, compared to placebo, as add-on treatment in patients with documented treatment-resistant schizophrenia (TRS) who have prospectively demonstrated inadequate response to their current stable therapeutic dose of an antipsychotic(s). Approximately 400 patients will be randomized equally (1:1) to each of the two treatment groups in this study.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Ravi Anand, MD
Newron Pharmaceuticals
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

15 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

India

Help Hospital
Vijayawada, Andhra Pradesh, India
Recruiting
Gauhati Medical College and Hospital
Guwahati, Assam, India
Recruiting
Masina Hospital Trust
Mumbai, Maharashtra, India
Recruiting
New Manak Healthcare Hospital
Navi Mumbai, Maharashtra, India
Recruiting
Ahana Hospitals Llp
Madurai, Tamil Nadu, India
Recruiting
Udyan Health Care
Lucknow, Uttar Pradesh, India
Recruiting
Seth Sukhlal Karnani Memorial Hospital
Kolkata, West Bengal, India
Not, yet, recruiting

Malaysia

Hospital Tuanku Fauziah
Kangar, Malaysia
Recruiting
Sentosa Hospital
Kuching, Malaysia
Recruiting
Sultan Abdul Halim Hospital
Sungai Petani, Malaysia
Recruiting

United States

Ucla Dgsom, Ucla Health, Ucla Semel Institute
Los Angeles, California, United States
Suspended
University of Miami, Miller School of Medicine; Jackson Behavioral Health Hospital
Miami, Florida, United States
Suspended
Grady Behavioral Health Center, -Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine
Atlanta, Georgia, United States
Suspended
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine
Baltimore, Maryland, United States
Suspended
Manhattan Psychiatric Center, the Nathan Kline Institute for Psychiatric Research
New York, New York, United States
Suspended

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

EvenamidePlacebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 23 Jan 2026
Primary completion: 31 Dec 2026
Completion: 31 Dec 2026
Last update posted: 30 Jul 2026
Registered enrollment: 400
Registry id: NCT07184619

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.